WEE1 and colorectal cancer: Multiple preclinical studies, including those in SCLC, breast, and colorectal cancers, demonstrate that SLFN11 loss can be overcome by targeting compensatory DDR pathways, particularly ATR, CHK1, and WEE1 (7, 56, 79, 80).